banner
 
bar

program

slides

  test

syllabus
bar
 
 

The Science and Medicine of
Circulatory Dysfunction and
Acute Pressure Syndromes

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Intended Audience:

This symposium has been conceived for the following audience:

  • Cardiologists, non-invasive specialists
  • Prevention-oriented cardiologists
  • Cardiologists, invasive specialists
  • Cardiovascu lar nurses
  • Coronary care unit (CCU) specialists and directors
  • Specialists in invasive vascular management
  • Program direc tors, cardiovascular medicine
  • Fellows in cardiovascular medi cine
  • Clinical pharmacists and pharmacologists
  • Pharmacy directors (cardiovascular medicine)
  • Investigators and clinical trial specialists, invasive cardiology

Registration:

Enrollment for this WebCAST is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

rocheSupported by an independent educational grant from The Medicines Company.
 

Accreditation Statement:

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School, Office of CME and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

The University of Massachusetts Medical School designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Faculty Disclosures:

Christopher B. Granger, MD
Educational Grants and/or Research Support: Alexion, Astra Zeneca, Procter and Gamble, sanofi-aventis, Novartis, The Medicines Company, Boehringer Ingelheim, Genentech, and Berlex

Ernesto L. Schiffrin, MD, PhD, FRSC, FRCPC, FACP
Grants/Research: Canadian Institutes of Health Research, Canadian Fund for Innovation, Merck-Frosst, Pfizer Cardiovascular Award
Consultant : Boehringer-Ingelheim, Bristol-Myers Squibb, Forest Pharmaceuticals, Novartis

Jerrold H. Levy, MD
Grant/Research Support: Alexion
Consultant: Bayer HealthCare, Dyax, Novo Nordisk, and Organon

Charles V. Pollack Jr, MA, MD, FACEP, FAAEM
Grant/Research Support: GlaxoSmithKline
Consultant: The Medicines Company, Schering-Plough, Sanofi-Aventis, BMS, Genentech
Speaker’s Bureau: Schering-Plough, Sanofi-Aventis, BMS, Genentech

Program Faculty:

PROGRAM FACULTY CHAIRMAN
Christopher B. Granger, MD, FACC

Professor, Department of Medicine
Division of Cardiology
Duke University Medical Center
Co-Director, Clinical Trials
Duke Clinical Research Institute (DCRI)
Durham, North Carolina

DISTINGUISHED FACULTY
Jerrold H. Levy, MD, FAHA

Professor and Deputy Chair for Research
Emory University School of Medicine
Director of Cardiothoracic Anesthesiology
Cardiothoracic Anesthesiology and Critical Care
Emory Healthcare
Atlanta, Georgia

Charles V. Pollack Jr, MA, MD, FACEP, FAAEM
Chairman, Dept. of Emergency Medicine
Pennsylvania Hospital
Professor of Emergency Medicine
University of Pennsylvania
School of Medicine
Philadelphia, Pennsylvania

Ernesto L. Schiffrin, MD, PhD, FRSC, FRCPC, FACP
Physician-in-Chief and Chairman
Department of Medicine
Sir Mortimer B. Davis — Jewish General Hospital
Canada Research Chair and Director
Hypertension and Vascular Research Unit
Lady Davis Institute for Medical Research.
Professor and Vice-Chair (Research)
Department of Medicine, McGill University
Montreal, PQ, Canada

Educational Objectives:

Participants in this CME-certified WebCAST will:

  • Learn to identify underlying chronic, acute, and perioperative precipitants of acute elevations in systemic blood pressure and how this syndrome presents across multiple cardiovascular disease states and patient populations.
  • Learn to assess and implement optimal pharmacologic interventions for patients presenting with manifestations of vascular/circulatory dysfunction and acute pressure syndromes, including elevated systolic or diastolic blood pressure, end organ dysfunction, and other cardiovascular, renovascular, and/or neurovascular derangements.
  • Learn to characterize, identify, and evaluate myriad, acute CV disease states producing serious and/or life-threatening elevations in systemic blood pressure, among them: hypertensive urgency, hypertensive crisis, ischemic stroke, drug-induced acute pressure syndromes, subarachnoid hemorrhage, intracerebral hemorrhage, pulmonary edema, and related conditions.
  • Learn to understand the specific advantages and potential disadvantages of currently available intravenously administered pharmacologic agents used to manage acute, serious, and/or life-threatening elevations in systemic blood pressure.
  • Learn to identify the ideal properties of intravenous agents used to provide cardiology-based lowering of potentially serious and/or life-threatening elevations in systemic blood pressure.
  • Learn to discuss and assess the impact that new trials and novel agents are likely to have on future management of patients with cardiovascular disease and acute pressure syndromes.
  • Will learn to apply national guidelines and expert, consensus-based recommendations in order to optimize therapy of patients with serious, systemic elevations in blood pressure

Disclaimer:

Copyright © 2008 by Pharmatecture, LLC. All rights reserved.
Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

bar

program

slides

  test

syllabus
bar

I have read this CME information statement and wish to participate in this CME activity.

Copyright © 2008 All rights reserved


 
6

 

Key Program Topics Include:

B-blockers
ACE Inhibitors
Acute coronary syndrome
Acute heart failure
Acute Myocardial Infarction
Acute Pressure Syndromes
Acute pulmonary edema
Acute renal failure
Anticoagulants
Antiplatelets
Aortic coarctation
Arrhythmia
ASA
aspirin
BP
Brain
Calcium Channel Blockers
Cardiopulmonary
Chest pain
Clevidipine
Clonidine
clopidogrel
CNS
Cushing’s syndrome
CVA


diabetes
Diastolic
Diazoxide
Dihydropyridine
Dissecting aorta
Diuretics
Dyspnea
Eclampsia
Elevated ICP
Emergency
End-Organ Damage
Epistaxis
Esmolol
Essential hypertension
Exudates
Fenoldopam
GP IIb/IIIa antagonist
Headache
Heart
Hemodynamics
Myocardial Ischemia
Heparin
Hydralazine
Hyperparathyroidism
Hypertension

 

Hypertensive
hypertensive crisis
Hypertensive Emergencies
Hypertensive encephalopathy
Hyperthyroidism
Isolated Systolic Hypertension
Kidneys
Labetolol
LMWH
Low molecular weight heparin
Lytic
MAP
MgSO4
Neurologic deficits
Neurologic Insult
Neurovascular Insults
Nicardipine
Nitrendipine
Nitroglycerin
Nitroprusside
Nitrovasodilators
Ocular
Organic Nitrates
Papilledema
PCWP
Perioperative hypertension
Pheochromocytoma
JNC 7
Pregnancy
Pregnancy-Induced HTN
Prehypertension
Primary aldosteronism
Psychomotor agitation
Rapid Onset of Effect
Reflex tachycardia
Renal
Renal dysfunction
Retinal hemorrhages
Secondary hypertension
Stage 1 hypertension
Stage 2 hypertension
Stage 3 hypertension
Systolic
UFH
Vascular Dysfunction Syndromes
VELOCITY